N-(2-溴-4-三氟甲基苯基)乙酰胺 | 175135-49-6

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: N-(2-溴-4-三氟甲基苯基)乙酰胺
• 中文别名: 4-乙酰氨基-3-溴苯并三氟；4-乙酰胺基-3-溴三氟甲苯
• 英文名称: N-(2-bromo-4-(trifluoromethyl)phenyl)acetamide
• 英文别名: 2-bromo-4-trifluoromethylacetanilide；4-Acetamido-3-bromobenzotrifluoride；N-[2-bromo-4-(trifluoromethyl)phenyl]acetamide
• CAS: 175135-49-6
• 化学式: C₉H₇BrF₃NO
• 分子量: 282.06
• InChiKey: SSPBNPXYQLCJTA-UHFFFAOYSA-N

物化性质

• 熔点：
  144-146°C
• 沸点：
  324.2±42.0 °C(Predicted)
• 密度：
  1.637±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.8
• 重原子数：
  15
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.22
• 拓扑面积：
  29.1
• 氢给体数：
  1
• 氢受体数：
  4

安全信息

• 危险品标志：
  Xi
• 安全说明：
  S26,S36/37/39
• 危险类别码：
  R36/37/38
• 海关编码：
  2924299090

SDS

Name:	N1-[2-bromo-4-(trifluoromethyl)phenyl]acetamide, 97% Material Safety Data Sheet
Synonym:	4-Acetamido-3-bromobenzotrifluoride
CAS:	175135-49-6

Section 1 - Chemical Product MSDS Name: N1-[2-bromo-4-(trifluoromethyl)phenyl]acetamide, 97% Material Safety Data Sheet
Synonym: 4-Acetamido-3-bromobenzotrifluoride

---

SECTION 2 - COMPOSITION, INFORMATION ON INGREDIENTS

CAS#	Chemical Name	content	EINECS#
175135-49-6	N1-[2-Bromo-4-(trifluoromethyl)phenyl]	97%	unlisted

+++++
Hazard Symbols: XN

---

SECTION 3 - HAZARDS IDENTIFICATION EMERGENCY OVERVIEW Harmful if swallowed. Irritating to eyes, respiratory system and skin. Potential Health Effects
Eye:
Causes eye irritation.
Skin:
Causes skin irritation. May be harmful if absorbed through the skin.
Ingestion:
Harmful if swallowed. May cause irritation of the digestive tract.
Inhalation:
Causes respiratory tract irritation. May be harmful if inhaled.
Chronic:
Not available.

---

SECTION 4 - FIRST AID MEASURES
Eyes:
Flush eyes with plenty of water for at least 15 minutes, occasionally lifting the upper and lower eyelids. Get medical aid.
Skin:
Get medical aid. Flush skin with plenty of water for at least 15 minutes while removing contaminated clothing and shoes.
Ingestion:
Get medical aid. Wash mouth out with water.
Inhalation:
Remove from exposure and move to fresh air immediately. If not breathing, give artificial respiration. If breathing is difficult, give oxygen. Get medical aid.
Notes to Physician:
Treat symptomatically and supportively.

---

SECTION 5 - FIRE FIGHTING MEASURES
General Information:
As in any fire, wear a self-contained breathing apparatus in pressure-demand, MSHA/NIOSH (approved or equivalent), and full protective gear.
Extinguishing Media:
Use water spray, dry chemical, carbon dioxide, or chemical foam.

---

SECTION 6 - ACCIDENTAL RELEASE MEASURES
General Information: Use proper personal protective equipment as indicated in Section 8.
Spills/Leaks:
Vacuum or sweep up material and place into a suitable disposal container.

---

SECTION 7 - HANDLING and STORAGE
Handling:
Avoid breathing dust, vapor, mist, or gas. Avoid contact with skin and eyes.
Storage:
Store in a cool, dry place. Store in a tightly closed container.

---

SECTION 8 - EXPOSURE CONTROLS, PERSONAL PROTECTION
Engineering Controls:
Facilities storing or utilizing this material should be equipped with an eyewash facility and a safety shower. Use adequate ventilation to keep airborne concentrations low. Exposure Limits CAS# 175135-49-6: Personal Protective Equipment
Eyes:
Not available.
Skin:
Wear appropriate protective gloves to prevent skin exposure.
Clothing:
Wear appropriate protective clothing to prevent skin exposure.
Respirators:
Follow the OSHA respirator regulations found in 29 CFR 1910.134 or European Standard EN 149. Use a NIOSH/MSHA or European Standard EN 149 approved respirator if exposure limits are exceeded or if irritation or other symptoms are experienced.

---

SECTION 9 - PHYSICAL AND CHEMICAL PROPERTIES
Physical State: Solid
Color: white
Odor: Not available.
pH: Not available.
Vapor Pressure: Not available.
Viscosity: Not available.
Boiling Point: Not available.
Freezing/Melting Point: 144 - 146 deg C
Autoignition Temperature: Not available.
Flash Point: Not available.
Explosion Limits, lower: Not available.
Explosion Limits, upper: Not available.
Decomposition Temperature:
Solubility in water:
Specific Gravity/Density:
Molecular Formula: C9H7BrF3NO
Molecular Weight: 282

---

SECTION 10 - STABILITY AND REACTIVITY
Chemical Stability:
Not available.
Conditions to Avoid:
Incompatible materials.
Incompatibilities with Other Materials:
Oxidizing agents.
Hazardous Decomposition Products:
Nitrogen oxides, carbon monoxide, carbon dioxide, hydrogen bromide, bromine, fluorine, hydrogen fluoride gas.
Hazardous Polymerization: Has not been reported

---

SECTION 11 - TOXICOLOGICAL INFORMATION RTECS#: CAS# 175135-49-6 unlisted.
LD50/LC50:
Not available.
Carcinogenicity:
N1-[2-Bromo-4-(trifluoromethyl)phenyl]acetamide - Not listed by ACGIH, IARC, or NTP.

---

SECTION 12 - ECOLOGICAL INFORMATION

---

SECTION 13 - DISPOSAL CONSIDERATIONS Dispose of in a manner consistent with federal, state, and local regulations.

---

SECTION 14 - TRANSPORT INFORMATION IATA No information available. IMO No information available. RID/ADR No information available.

---

SECTION 15 - REGULATORY INFORMATION European/International Regulations European Labeling in Accordance with EC Directives
Hazard Symbols: XN
Risk Phrases:
R 22 Harmful if swallowed. R 36/37/38 Irritating to eyes, respiratory system and skin.
Safety Phrases:
S 26 In case of contact with eyes, rinse immediately with plenty of water and seek medical advice. S 37/39 Wear suitable gloves and eye/face protection. WGK (Water Danger/Protection) CAS# 175135-49-6: No information available. Canada None of the chemicals in this product are listed on the DSL/NDSL list. CAS# 175135-49-6 is not listed on Canada's Ingredient Disclosure List. US FEDERAL TSCA CAS# 175135-49-6 is not listed on the TSCA inventory. It is for research and development use only.

---

SECTION 16 - ADDITIONAL INFORMATION
MSDS Creation Date: 6/10/2003 Revision #0 Date: Original. The information above is believed to be accurate and represents the best information currently available to us. However, we make no warranty of merchantability or any other warranty, express or implied, with respect to such information, and we assume no liability resulting from its use. Users should make their own investigations to determine the suitability of the information for their particular purposes. In no way shall the company be liable for any claims, losses, or damages of any third party or for lost profits or any special, indirect, incidental, consequential or exemplary damages, howsoever arising, even if the company has been advised of the possibility of such damages.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  N-(2-溴-4-三氟甲基苯基)乙酰胺 在 copper(l) iodide 、 (1R,2R)-(-)-N,N'-二甲基-1,2-环己二胺 、 sodium iodide 作用下， 以 戊醇 为溶剂， 反应 24.0h， 生成 N-(2-iodo-4-(trifluoromethyl)phenyl)acetamide
  参考文献：
  名称：

  Copper-Catalyzed Regiospecific Synthesis of N-Alkylbenzimidazoles

  摘要：

  A copper-catalyzed method is described for the preparation of N-alkylbenzimidazoles in regioisomerically pure form starting from o-haloanilines. The method utilizing CuI and trans-N,N'-dimethyl-1,2-cyclohexanediamine allows the preparation of N-alkylbenzimidazoles in good to excellent yields.

  DOI：

  10.1021/ol7020737
• 作为产物：
  描述：

  N1-[4-(三氟甲基0苯基]乙酰氨 在 乙酸酐 、 copper(II) bis(trifluoromethanesulfonate) 、 N-氟代双苯磺酰胺 、 sodium bromide 作用下， 以 乙腈 为溶剂， 以53%的产率得到N-(2-溴-4-三氟甲基苯基)乙酰胺
  参考文献：
  名称：

  N-氟苯磺酰亚胺铜催化苯胺区域选择性卤化

  摘要：

  已开发出具有优异区域选择性和单取代的铜催化苯胺直接氯化和溴化。该协议提供了在温和条件下使用廉价的 KCl 或 NaBr 作为卤素源从容易获得的芳烃中获得广泛的芳烃氯化物和溴化物的途径。

  DOI：

  10.1002/ejoc.202200399

文献信息

• [EN] BIPHENYL SUBSTITUTED 1,3-DIHYDRO-BENZOIMIDAZOL-2-YLIDENEAMINE DERIVATIVES<br/>[FR] DÉRIVÉS DE 1,3-DIHYDRO-BENZOIMIDAZOL-2-YLIDÈNE-AMINE À SUBSTITUTION BIPHÉNYLE
  申请人：NOVARTIS AG

  公开号：WO2011157787A1

  公开（公告）日：2011-12-22

  The invention relates to new derivatives of formula (I), wherein the substituents are as defined in the specification; to processes for the preparation of such derivatives; pharmaceutical compositions comprising such derivatives; such derivatives as a medicament; such derivatives for the treatment of one or more IGF-1 R mediated disorders or diseases.

  这项发明涉及公式（I）的新衍生物，其中取代基如规范中所定义；制备这种衍生物的方法；包括这种衍生物的药物组合物；将这种衍生物用作药物；将这种衍生物用于治疗一个或多个IGF-1 R介导的疾病。
• [EN] SULFONAMIDE COMPOUNDS AS VOLTAGE-GATED SODIUM CHANNEL MODULATORS<br/>[FR] COMPOSÉS DE SULFONAMIDE À TITRE DE MODULATEURS DES CANAUX SODIQUES VOLTAGE-DÉPENDANTS
  申请人：LUPIN LTD

  公开号：WO2017037682A1

  公开（公告）日：2017-03-09

  The present invention relates to sulfonamide compounds Formula (I) wherein the substituents are as described herein, and their use in a medicine for the treatment of diseases, disorders associated with the inhibition of Voltage-gated sodium channels (VGSC) particularly NaV1.7. It further relates to the compounds herein and their pharmaceutically acceptable salts thereof, pharmaceutical compositions thereof useful in treating diseases, disorders, syndromes and/or conditions associated with the inhibition of Voltage-gated sodium channels (VGSC) particularly NaV1.7. The invention also relates to process for the preparation of the compounds of the invention. (I)

  本发明涉及磺胺基化合物Formula (I)，其中取代基如本文所述，并其在治疗与抑制电压门控钠通道(VGSC)特别是NaV1.7相关的疾病、疾病和障碍中的用途。它进一步涉及本文中的化合物及其药学上可接受的盐，以及用于治疗与抑制电压门控钠通道(VGSC)特别是NaV1.7相关的疾病、疾病、综合症和/或症状的药物组合物。该发明还涉及制备本发明化合物的方法。(I)
• Discovery of Potent, Selective, and State-Dependent Na_V1.7 Inhibitors with Robust Oral Efficacy in Pain Models: Structure–Activity Relationship and Optimization of Chroman and Indane Aryl Sulfonamides
  作者：Vidya Ramdas、Rashmi Talwar、Vijay Kanoje、Rajesh M. Loriya、Moloy Banerjee、Pradeep Patil、Advait Arun Joshi、Laxmikant Datrange、Amit Kumar Das、Deepak Sahebrao Walke、Vaibhav Kalhapure、Talha Khan、Ganesh Gote、Usha Dhayagude、Shreyas Deshpande、Javed Shaikh、Ganesh Chaure、Ravindra R. Pal、Santosh Parkale、Sachin Suravase、Smita Bhoskar、Rajesh V. Gupta、Anil Kalia、Rajesh Yeshodharan、Mahammad Azhar、Jagadeesh Daler、Vinod Mali、Geetika Sharma、Amitesh Kishore、Rupali Vyawahare、Gautam Agarwal、Himani Pareek、Sagar Budhe、Arun Nayak、Dnyaneshwar Warude、Praveen Kumar Gupta、Parag Joshi、Sneha Joshi、Sagar Darekar、Dilip Pandey、Akshaya Wagh、Prashant B. Nigade、Maneesh Mehta、Vinod Patil、Dipak Modi、Shashikant Pawar、Mahip Verma、Minakshi Singh、Sudipto Das、Jayasagar Gundu、Kumar Nemmani、Mark G. Bock、Sharad Sharma、Dhananjay Bakhle、Rajender Kumar Kamboj、Venkata P. Palle

  DOI：10.1021/acs.jmedchem.0c00361

  日期：2020.6.11

  Voltage-gated sodium channel NaV1.7 is a genetically validated target for pain. Identification of NaV1.7 inhibitors with all of the desired properties to develop as an oral therapeutic for pain has been a major challenge. Herein, we report systematic structure–activity relationship (SAR) studies carried out to identify novel sulfonamide derivatives as potent, selective, and state-dependent NaV1.7 inhibitors

  电压门控钠通道Na V 1.7是经遗传验证的疼痛靶标。鉴定具有所有所需特性的Na V 1.7抑制剂以开发为口服疼痛治疗剂一直是一项重大挑战。在这里，我们报告进行系统的结构-活性关系（SAR）研究，以鉴定新型磺酰胺衍生物作为强效，选择性和状态依赖性Na V 1.7疼痛抑制剂。从苯并恶嗪跃迁至苯并二氢吡喃和茚满双环体系，然后在磺酰胺上用噻唑置换，导致铅分子的溶解度，对Na V 1.5的选择性和对CYP2C9的抑制均得到显着改善。引线分子13，29，32，43，和51显示出在不同的物种和藜芦健壮功效和在小鼠福尔马林诱导的炎性疼痛模型的有利的药代动力学（PK）曲线。化合物51还显示出对CCI诱导的神经性疼痛模型的显着影响。51的图谱表明它有潜力进一步评估其作为疼痛的治疗剂。
• Pyridine derivatives and pharmaceutical compositions containing them
  申请人：AstraZeneca AB

  公开号：US06300352B1

  公开（公告）日：2001-10-09

  The invention relates to novel pyridyl derivatives, their use as medicaments, pharmaceutical formulations containing them and methods for their preparation.

  这项发明涉及新型吡啶衍生物，其用作药物，含有它们的药物配方以及它们的制备方法。
• Synthesis and antileishmanial activity of fluorinated rhodacyanine analogues: The ‘fluorine-walk’ analysis
  作者：Thitiya Lasing、Atchara Phumee、Padet Siriyasatien、Kantima Chitchak、Parichatr Vanalabhpatana、Kit-Kay Mak、Chew Hee Ng、Tirayut Vilaivan、Tanatorn Khotavivattana

  DOI：10.1016/j.bmc.2019.115187

  日期：2020.1

  These compounds were tested for their inhibitory activities against Leishmania martiniquensis and L. orientalis. This 'fluorine-walk' analysis revealed that the introduction of fluorine atom at C-5, 6, 5', or 6' on the benzothiazole units led to significant enhancement of the activity, correlating with the less negative reduction potentials of the fluorinated analogues confirmed by the electrochemical study

  为了寻找有效的抗衰老药物候选物，合成了十八个在不同位置带有氟或全氟烷基取代基的若丹菁类似物。测试了这些化合物对利什曼原虫马提尼丘菌和东方乳杆菌的抑制活性。该“氟游走”分析表明，在苯并噻唑单元的C-5、6、5'或6'处引入氟原子可显着增强活性，这与氟化类似物的负还原电位较小有关经电化学研究证实。另一方面，发现CF 3和OCF 3基团具有有害作用，这与通过计算机模拟ADMET分析预测的较差的水溶性相吻合。此外，